Molekularpathologie gastrointestinaler Tumoren-Reference-Cited by-同舟云学术

Molekularpathologie gastrointestinaler Tumoren

Published:2024-03-28 Issue:3 Volume:19 Page:225-233
ISSN:2731-7420
Container-title:Die Gastroenterologie
language:de
Short-container-title:Gastroenterologie

Author:

Bedau Tillmann,Quaas Alexander

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11377-024-00777-9.pdf

Reference35 articles.

1. Anderson WF, Rabkin CS, Turner N et al (2018) The Changing Face of Noncardia Gastric Cancer Incidence Among US Non-Hispanic Whites. J Natl Cancer Inst 110:608–615. https://doi.org/10.1093/jnci/djx262

2. Cervantes A, Adam R, Roselló S et al (2023) Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34:10–32. https://doi.org/10.1016/j.annonc.2022.10.003

3. Ciardiello D, Chiarazzo C, Famiglietti V et al (2022) Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM). ESMO Open 7:100567. https://doi.org/10.1016/j.esmoop.2022.100567

4. Demetri GD, De Braud F, Drilon A et al (2022) Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clin Cancer Res 28:1302–1312. https://doi.org/10.1158/1078-0432.CCR-21-3597

5. ESMO (2023) ESMO Gastric Cancer Living Guideline: HER2-positive in Second or Further Lines of Treatment. https://www.esmo.org/living-guidelines/esmo-gastric-cancer-living-guideline/metastatic-disease/metastatic-disease/second-line/advanced-metastatic-unresectable-oesophageal-oesophagogastric-junction-and-gastric-adenocarcinoma/article/her2-positive-in-second-or-further-lines-of-treatment. Zugegriffen: 22. Jan. 2024